

NOV 24 2003

FORM PTO-1449 (Modified)
Approved for use through 12/31/2002US DEPARTMENT OF COMMERCE
US Patent and Trademark OfficeDocket No.
50623.325Application No.
10/632,739INFORMATION DISCLOSURE CITATION
in an Application

(Use several sheets if necessary)

Applicant
Yung-Ming Chen et al.Filing Date
August 1, 2003Group Art Unit
1614 1762

U.S. PATENT DOCUMENTS

Examiner Initial	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date if Appropriate
/RC/	A1	2,072,303	03/02/37	Herrmann et al.	128	335.5	
	A2	4,733,665	03/29/88	Palmaz	128	343	
	A3	4,800,882	01/31/89	Gianturco	128	343	
	A4	4,886,062	12/12/89	Wiktor	128	343	
	A5	4,977,901	12/18/90	Ofstead	128	772	
	A6	4,985,285	01/1991	Ichikawa et al.	428	1.31	
	A7	5,112,457	05/12/92	Marchant	204	165	
	A8	5,328,471	07/12/94	Slepian	604	101	
	A9	5,455,040	10/03/95	Marchant	424	426	
	A10	5,464,650	11/07/95	Berg et al.	427	2.30	
	A11	5,578,073	11/26/96	Haimovich et al.	623	1	
	A12	5,605,696	02/25/97	Eury et al.	424	423	
	A13	5,628,730	05/13/97	Shapland et al.	604	21	
	A14	5,667,767	09/16/97	Greff et al.	424	9.411	
	A15	5,670,558	09/23/97	Onishi et al.	523	112	
	A16	5,700,286	12/23/97	Tartaglia et al.	623	1	
	A17	5,716,981	02/10/98	Hunter et al.	514	449	
	A18	5,756,553	05/1998	Iguchi et al.	514	772.3	
	A19	5,770,301	06/1998	Murai et al.	428	213	
	A20	5,800,392	09/01/98	Racchini	604	96	
✓	A21	5,824,049	10/20/98	Ragheb et al.	623	1	
/RC/	A22	5,830,178	11/03/98	Jones et al.	604	49	
	A23	5,837,313	11/17/98	Ding et al.	427	2.21	

EXAMINER

Rosie Chang/

DATE CONSIDERED

03/14/2007

EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.

O I P E
NOV 24 2003
U.S. DEPARTMENT OF COMMERCE
US Patent and Trademark Office

BEST AVAILABLE COPY

Page 2 of 4

FORM PTO-1449 (Modified) Approved for use through 10/31/2002		US DEPARTMENT OF COMMERCE US Patent and Trademark Office		Docket No. 50623.325	Application No. 10/632,739		
INFORMATION DISCLOSURE CITATION in an Application (Use several sheets if necessary)				Applicant Yung-Ming Chen et al.			
				Filing Date August 1, 2003	Group Art Unit 1762 1614		
U.S. PATENT DOCUMENTS							
Examiner Initial	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date if Appropriate
/RC/	A24	5,851,508	12/22/98	Greff et al.	424	9.411	
	A25	5,858,746	01/12/99	Hubbell et al.	435	177	
	A26	5,865,814	02/02/99	Tuch	604	265	
	A27	5,873,904	02/23/99	Ragheb et al.	623	1	
	A28	5,971,954	10/26/99	Conway et al.	604	96	
	A29	5,980,972	11/09/99	Ding	427	2.24	
	A30	5,980,928	11/09/99	Terry	424	427	
	A31	6,010,530	01/04/00	Goicoechea	623	1	
	A32	6,015,541	01/18/00	Greff et al.	424	1.25	
	A33	6,042,875	03/28/00	Ding et al.	427	2.24	
	A34	6,051,648	04/18/00	Rhee et al.	525	54.1	
	A35	6,056,993	05/02/00	Leidner et al.	427	2.25	
	A36	6,060,451	05/09/00	DiMaio et al.	514	13	
	A37	6,080,488	06/27/00	Hostettler et al.	428	423.3	
	A38	6,096,070	08/01/00	Ragheb et al.	623	1	
	A39	6,099,562	08/08/00	Ding et al.	623	1.46	
	A40	6,110,188	08/29/00	Narciso, Jr.	606	153	
	A41	6,113,629	09/05/00	Ken	623	1.1	
	A42	6,120,536	09/19/00	Ding et al.	623	1.43	
	A43	6,120,904	09/19/00	Hostettler et al.	428	423.3	
	A44	6,121,027	09/19/00	Clapper et al.	435	180	
✓	A45	6,129,761	10/10/00	Hubbell	623	11	
/RC/	A46	6,153,252	11/28/00	Hossainy et al.	427	2.3	
EXAMINER /Rosie Chang/				DATE CONSIDERED	03/14/2007		

EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)
Approved for use through 10/31/2002

US DEPARTMENT OF COMMERCE
US Patent and Trademark Office

Docket No.
50623.325

Application No.
10/632,739

**INFORMATION DISCLOSURE CITATION
in an Application**

(Use several sheets if necessary)

Applicant
Yung-Ming Chen et al.

Filing Date
August 1, 2003

Group Art Unit
1614 1762

U.S. PATENT DOCUMENTS

Examiner Initial	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date if Appropriate
/RC/	A47	6,165,212	12/26/00	Dereume et al.	623	1.13	
	A48	6,258,121	07/10/01	Yang et al.	623	1.46	
	A49	6,287,588	09/2001	Shih et al.	424	426	
✓	A50	6,335,029	01/2002	Kamath et al.	424	423	
/RC/	A51	6,368,658	04/2002	Schwarz et al.	427	2.15	

FOREIGN PATENT DOCUMENTS

Examiner Initial	Ref. No.	Document Number	Date of Publication	Country	Class	Subclass	Translation	
							Yes	No
/RC/	B1	EP 0 301 856 A2	02/01/89	European				
	B2	WO 91/12846	09/05/91	PCT				
	B3	EP 0 665 023 A1	08/02/95	European				
	B4	WO 96/40174	12/19/96	PCT				
	B5	WO 97/45105	12/04/97	PCT				
	B6	WO 99/01118	01/14/99	PCT				
	B7	WO 99/63981	12/16/99	PCT				
	B8	EP 0 970 711 A2	01/12/00	European				
	B9	WO 00/02599	01/20/00	PCT				
	B10	WO 00/12147	03/09/00	PCT				
✓	B11	WO 00/64506	11/02/00	PCT				
/RC/	B12	WO 01/01890 A1	01/11/01	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

/RC/	C1	Miyazawa et al.; Effects of Pemirolast and Tranilast on Intimal Thickening After Arterial Injury in the Rat; J Cardiovasc Pharmacol 1997; 157
/RC/	C2	Ohsawa et al.; Preventive Effects of an Antiallergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty; Am Heart J 1998; 136: 1081

EXAMINER	/Rosie Chang/	DATE CONSIDERED	03/14/2007
----------	---------------	-----------------	------------

EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)
Approved for use through 10/31/2002

US DEPARTMENT OF COMMERCE
US Patent and Trademark Office

Docket No.
50623.325

Application No.
10/632,739

**INFORMATION DISCLOSURE CITATION
in an Application**

(Use several sheets if necessary)

Applicant
Yung-Ming Chen et al.

Filing Date
August 1, 2003

1614

1762

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

/RC/	C3	Shozo Miyazaki, et al.; Antitumor Effect of Implanted Ethylene-Vinyl Alcohol Copolymer Matrices Containing Anticancer Agents on Ehrlich Ascites Carcinoma and P388 Leukemia in Mice; 1985; Chem. Pharm. Bull. Vol. 33, No. 6, Pages 2490-2498.
	C4	Peter Barath, M.D. et al.; Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury; February 1989; JACC Vol. 13, No. 2, Page 252 A.
↓	C5	Taku Shigeno; Prevention of Cerebrovascular Spasm by Bosentan, Novel Endothelin Receptor; 1996; Kanto Rosai Hosp., Kawasaki, 211, Japan; 6(4), 416-421.
/RC/	C6	Yuji Matsumaru et al.; Embolic Materials For Endovascular Treatment Of Cerebral Lesions; 1997; J. Biomater. Sci. Polymer Edn. Vol. 8, No. 7, Pages 555-569.
EXAMINER	/Rosie Chang/	DATE CONSIDERED 03/14/2007

EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.

BEST AVAILABLE COPY